

Idorsia Company Profile

Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is specialized in the discovery, development, and commercialization of transformative medicines.

We have a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients.

Financial overview	First Half			
	US GAAP		Non-GAAP*	
in CHF millions, except EPS (CHF) and number of shares (millions)	2025	2024	2025	2024
Net revenues	131	26	130	26
Operating expenses	(75)	(94)	(152)	(200)
Operating income (loss)	64	(64)	(15)	(170)
Net income (loss)	52	(79)	(25)	(183)
Basic EPS	0.26	(0.44)	(0.13)	(1.02)
Basic weighted average number of shares	195.3	179.5	195.3	179.5
Diluted EPS	0.26	(0.44)	(0.13)	(1.02)
Diluted weighted average number of shares	195.9	179.5	195.3	179.5

The full financial statements can be found in the Financial Report available on our corporate website.

* Idorsia measures, reports and issues guidance on non-GAAP operating performance. Idorsia believes that these non-GAAP financial measurements more accurately reflect the underlying business performance and therefore provide useful supplementary information to investors. These non-GAAP measures are reported in addition to, not as a substitute for, US GAAP financial performance.

Company Profile

> Financial overview

Company strategy

Innovation portfolio

Company milestones

Share Information

Idorsia was incorporated in March 2017 and listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017.

Idorsia Ltd is part of the following indices: SPI, SPIEX, SPI ESG, SXSLI, SXI Life Sciences, SXI Bio+Medtech, and SSIRT.

Idorsia is traded under the following symbols:
Reuters IDIA.S / Bloomberg IDIA:SW.

Company Strategy

We will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. We have identified five key strategic priorities to bring the company to overall profitability starting from the end of 2027:

Unlocking the full value of QUVIVIQ

Accelerate commercial momentum by expanding reach to patients, optimizing our market presence, and generating evidence supporting medical utility to realize the full potential of QUVIVIQ.

Expand strategic partnerships

Strengthen current alliances and actively pursue new, high-impact partnerships to scale access and commercialization, accelerate development, and enhance long-term value creation.

Advance our differentiated pipeline assets

Focus on innovation that alters the course of disease. Prioritize smart, efficient R&D, and engage in targeted collaborations to expand capacity and impact.

Operate with financial discipline

Balance ambition with accountability. Stay laser-focused on resource allocation, cost discipline, and value-driven decisions.

Empower our people to achieve excellence

Invest in a high-performance culture grounded in clarity, collaboration, and ownership. Enable teams to move with speed, adapt with agility, and deliver meaningful results.

Company Profile

Financial overview

> Company strategy

Innovation portfolio

Company milestones

Key portfolio assets

Compound	Target indication	Mechanism of action	P1	P2	P3	R	C	Status
QUVIVIQ™ (daridorexant)	Insomnia	Dual orexin receptor antagonist	■	■	■	■	■	Commercially available in the US, Germany, Italy, Switzerland, Spain, the UK, Canada, Austria, France, Sweden and Finland; approved throughout the EU
Lucerastat	Fabry disease	Glucosylceramide synthase inhibitor	■	■	■	□	□	New data and evaluation of long-term treatment with lucerastat supportive further investigation – regulatory pathway to be discussed with the FDA
Daridorexant	Pediatric insomnia	Dual orexin receptor antagonist	■	■	□	□	□	Phase 2 in pediatric insomnia ongoing
ACT-777991	Vitiligo	CXCR3 antagonist	■	■	□	□	□	Proof-of-concept study in preparation
ACT-1004-1239	Progressive multiple sclerosis	CXCR7 / ACKR3 receptor antagonist	■	■	□	□	□	Proof-of-concept study in preparation
IDOR-1117-2520	Psoriasis	CCR6 receptor antagonist	■	■	□	□	□	Proof-of-concept study in preparation
Synthetic Glycan Vaccine Platform			Idorsia will seek a partner for the platform or individual vaccines					
IDOR-1134-2831	<i>Clostridium difficile</i> infection	Synthetic glycan vaccine	■	□	□	□	□	Initial Phase 1 data showing safety and immunogenicity

P1: Phase 1, P2: Phase 2, P3: Phase 3, R: Registration, C: Commercially available
 For more information about our portfolio please read our [Innovation fact sheet](#).

Company Profile

Financial overview

Company strategy

> Innovation portfolio

Company milestones

Partner-led portfolio

Compound	Target indication	Mechanism of action	Partner Terms	P1	P2	P3	R	C	Status
TRYVIO™ (aprocitentan)	Systemic hypertension in combination with other antihypertensives	Dual endothelin receptor antagonist	In partnership discussions: worldwide development and commercialization rights	■	■	■	■	■	Commercially available in the US
JERAYGO™ (aprocitentan)	Resistant hypertension in combination with other antihypertensives	Dual endothelin receptor antagonist	In partnership discussions: worldwide development and commercialization rights	■	■	■	■	□	Approved in the EU and UK; Marketing authorization applications submitted in Canada, and Switzerland
QUVIVIQ™ (daridorexant)	Insomnia	Dual orexin receptor antagonist	Nxera Pharma: license to develop and commercialize for Asia-Pacific region (excluding China)	■	■	■	■	■	Launched for the treatment of insomnia in Japan; Phase 3 ongoing in South Korea
QUVIVIQ™ (daridorexant)	Insomnia	Dual orexin receptor antagonist	Simcere: license to develop and commercialize for Greater China region	■	■	■	■	□	Approved for the treatment of insomnia in China and Hong-Kong
Selatogrel	Acute myocardial infarction	P2Y ₁₂ inhibitor	Viatis: worldwide development and commercialization rights	■	■	■	□	□	Phase 3 "SOS-AMI" program ongoing
Cenerimod	Systemic lupus erythematosus	S1P ₁ receptor modulator	Viatis: worldwide development and commercialization rights	■	■	■	□	□	Phase 3 "OPUS" program ongoing
Daridorexant	Posttraumatic stress disorder (PTSD)	Dual orexin receptor antagonist	US Department of Defense (DOD): Idorsia is supporting a clinical study sponsored by the US DOD to develop new therapies to treat PTSD	■	■	□	□	□	Phase 2 ongoing
ACT-1002-4391	Immuno-oncology	EP ₂ /EP ₄ receptor antagonist	Owkin: global license to develop and commercialize	■	□	□	□	□	Phase 1 ongoing

P1: Phase 1, P2: Phase 2, P3: Phase 3, R: Registration, C: Commercially available
For more information about our partnerships please visit the [corporate website](#)

Company Profile

Financial overview

Company strategy

> Innovation portfolio

Company milestones

Company milestones

2025

June New data and evaluation of long-term treatment with lucerastat supportive further investigation

June Idorsia's synthetic glycan *C. difficile* vaccine directly targeting bacteria and spores shows safety and immunogenicity in humans

June Simcere receives approval for QUVIVIQ in China

June QUVIVIQ launched in Finland

January JERAYGO™ approved by the UK MHRA

2024

September QUVIVIQ launched in Sweden

June JERAYGO approved by the European Union's EMA

March TRYVIO™ approved by the US FDA

March QUVIVIQ launched in France

March Global development and commercialization agreement with Viatrix for selatogrel and cenerimod

February QUVIVIQ launched in Austria

2023

November QUVIVIQ launched in Canada

October QUVIVIQ launched in the UK

September QUVIVIQ launched in Spain

June QUVIVIQ launched in Switzerland

Company Profile

Financial overview

Company strategy

Innovation portfolio

> Company milestones

2022

December OPUS Phase 3 program to investigate cenerimod for the treatment of patients with systemic lupus erythematosus initiated

November QUVIVIQ launched in Germany and Italy

November The Lancet and American Heart Association late-breaking science session reports significant and sustained effect of aprocitantan on lowering blood pressure for patients with resistant hypertension

May Europe's first dual orexin receptor antagonist – QUVIVIQ – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder

May QUVIVIQ launched in the US

January The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia

2021

December Idorsia to further characterize lucerastat for Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study

September Five Idorsia affiliates in key European markets (France, Germany, Italy, Spain, UK) established

June Initiation of Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction

2020

July Establishment of Idorsia Pharmaceuticals US Inc. to perform commercial operations

2017

June Idorsia opens its doors and is listed on SIX Swiss Stock Exchange

Company Profile

Financial overview

Company strategy

Innovation portfolio

> **Company milestones**



Idorsia is an independent biopharmaceutical company based on science and innovation. The company is specialized in the discovery, development, and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options. It is headquartered in Allschwil/Basel, Switzerland and is quoted on the SIX Swiss Exchange (tickersymbol: IDIA). All trademarks are legally protected by their respective owners.

Disclaimer This fact sheet has the sole purpose to provide members of the public with general information about the activities of Idorsia. The forward-looking statements in this fact sheet are based on current expectations and belief of company management, which are subject to numerous risks and uncertainties.

Idorsia Pharmaceuticals Ltd

Hegenheimerweg 91
4123 Allschwil
Switzerland

investor.relations@idorsia.com
Phone +41 58 844 10 10
www.idorsia.com



**Company
Profile**

Latest update:
July 2025
Copyright © 2025 Idorsia